ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1136

The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts

Bayram Farisogullari1, Pedro Machado2, Stephanie Finzel3, Graeme Carroll4, Geraldine mcCarthy5, John Stack6, Simone Parisi7, Graca Porto8, richette pascal9, Gyorgy Nagy10, Marton Weidl10, Ann Rosenthal11, Pascal Guggenbuhl12, Katarzyna Banaszkiewicz13, Barbara Butzeck14, Howard Don15, Svenja Engelhardt16, Jeremy Shearman17, David Mitchell18, Jane Barker19, Valerie Brueton19, Philip Coathup19, Jacquie Dowsett19, Marie Duncan19, Tracey Dunleavy19, Ian Fish19, Allin Hoggarth19, Mark McKinnon19, James Minter19, Tim Osborne19, Marguerite Smith19, Christine Wright19 and Patrick Kiely20, 1University College London, London, 2Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 3Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 4Fiona Stanley Hospital, Perth, Western Australia, Australia, 5Mater Misericordiae University Hospital, Dublin, Ireland, 6Mater Misericordiae University Hospital, Dublin, Dublin, Ireland, 7Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, 8Centro Hospitalar Universitário de Santo António, Unidade Local de Saúde de Santo António, Porto, Portugal, 9Rheumatology Department, Lariboisiere Hospital, Paris, Ile-de-France, France, 10Buda Hospital of the Hospitaller Order of Saint John of God, Budapest, Hungary, 11Department of Medicine, Division of Rheumatology, Medical College of Wisconsin, Wisconsin, 12Rennes University Hospital, Rennes, France, 13University Clinical Center in Gdańsk, Smoluchowskiego 17 Street, 80-952 Gdańsk, Poland., Gdańsk, Poland, 14European Federation of Associations of Patients with Haemochromatosis,, Croissy-sur-Seine, France, 15Haemochromatosis International, Barnstaple, United Kingdom, 16University of Freiburg, Freiburg im Breisgau, Germany, 17South Warwickshire University Foundation Trust and Warwick Medical School,, Warwick, United Kingdom, 18Clongriffin Medical Centre, Dublin, Ireland, 19c/o St George's University Hospitals NHS Trust, London, United Kingdom, 20St George's University Hospitals NHS Foundation Trust, London, United Kingdom

Meeting: ACR Convergence 2025

Keywords: classification criteria, Crystal-induced arthritis, Imaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: A EULAR task force developed classification criteria (CC) for Haemochromatosis Arthropathy (HA) using a cohort of people with the C282Y homozygous mutation and arthropathy with iron overload requiring phlebotomy (1). The CC include 8 items covering age of symptom onset, clinical and X-ray features at MCP, DIP and ankle joints, and surgery of hips or ankles. A score of ≥5/11 provides 93.3% specificity and 71.4% sensitivity for classifying HA.Two additional cohorts were recruited, both without iron overload; 1. Arthropathy and any HFE gene mutation, and 2. Disease mimics (OA, CPPD). This study aimed to assess the role of iron overload and HFE gene mutations on joint disease expression by comparing the performance of the HA CC and its individual items across the 3 cohorts.

Methods: The HA cohorts included 373 patients from 12 centres across 10 countries. Group 1 (G1, n=154): C282Y homozygous with arthropathy and iron overload; Group 2 (G2, n=99): any HFE mutation with arthropathy and no iron overload; Group 3 (G3, n= 120): disease mimics (OA, CPPD).We compared features of arthropathy in G1 with G2, and G2 with G3, also with G2 subgroups: C282Y homozygous and heterozygous, H63D homozygous and heterozygous, C282Y/H63D compound heterozygous, any C282Y and compound heterozygotes, any H63D and compound heterozygotes. The total CC score, prevalence of the 8 items and proportion of patients scoring ≥5/11 to fulfil CC, was compared between groups using the Chi-square/Fisher’s exact tests or the independent sample T-test, as appropriate.

Results: Six of eight CC items were significantly more prevalent in G1 vs G2, and 5 of 8 items in G2 vs G3. The mean total score in G1 was 6.0, G2 4.3, p < 0.001 (G1 vs G2), and G3 2.7, p < 0.001 (G2 vs G3). The CC for HA were met in 71.4% of G1, 37.4% of G2 and 6.7% of G3 (p < 0.001 G1 vs G2 and G2 vs G3).Genotype-stratified analysis of G2 revealed a consistent hierarchy in prevalence of 5 of 8 of the individual CC items, total CC score and fulfilment of the CC overall. The highest prevalence was seen in people with H63D homozygous or heterozygous mutations combined, followed by any H63D and compound heterozygotes, followed by either any C282Y and compound heterozygotes or C282Y homozygous or heterozygous mutations alone (Table 1 & 2).

Conclusion: The discriminatory features of joint disease in HA, as defined by the CC, are significantly more prevalent in patients with iron overload and the C282Y homozygous HFE mutation than in patients without iron overload and any HFE genotype, supporting the major role of iron in disease expression. In patients without iron overload and with any HFE mutation, the discriminatory features of HA are significantly more prevalent than found in OA and CPPD disease mimics, supporting an iron-independent effect of HFE mutations on arthropathy. This appears to be most evident in patients with any H63D mutation, though subgroup numbers are low. Overall, these findings increase our understanding of the interplay between HFE mutations and iron status in the pathogenesis of HA, where HFE mutations alone are associated with the phenotypic features of HA, becoming much accentuated with iron loading.Reference: < !1. Kiely et al EULAR Classification Criteria for Haemochromatosis Arthropathy. ARD 2025; POS0558

Supporting image 1Table 1. Comparison of EULAR HA Classification Criteria component items, total score and fulfilment of the criteria in HFE C282Y homozygous patients with iron overload (Group 1) and patients without iron overload, stratified by HFE Mutation Status (Group 2).

p values refer to comparisons with Group 1, statistical significance p < 0.05

Supporting image 2Table 2. Comparison of EULAR HA Classification Criteria Features in patients with HFE mutations with no iron overload (Group 2) and patients with disease mimics (OA, CPPD, Group 3). Group 2 stratified by HFE Mutation Status.

p values refer to comparisons with Group 3, statistical significance p < 0.05


Disclosures: B. Farisogullari: None; P. Machado: AbbVie/Abbott, 2, 6, Eli Lilly, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, UCB, 2, 6; S. Finzel: AbbVie/Abbott, 6, Alfasigma/Galapagos, 6, 12, meeting or travel grant, AstraZeneca, 2, Biotest, 6, 12, meeting or travel grant, Celltrion, 6, Chugai, 6, Eli Lilly, 12, meeting or travel grant, GlaxoSmithKlein(GSK), 2, 6, Johnson&Johnson, 2, 6, 12, meeting or travel grant, Novartis, 2, 6, 12, meeting or travel grant, NovoNordisk, 2, Sobi, 12, meeting or travel grant, UCB, 2, 6, 12, meeting or travel grant; G. Carroll: None; G. mcCarthy: PK Med and Avalo, 2; J. Stack: Janssen, 12, Support to attend meetings, UCB, 12, Support to attend meetings; S. Parisi: None; G. Porto: None; r. pascal: None; G. Nagy: None; M. Weidl: None; A. Rosenthal: None; P. Guggenbuhl: Amgen, 6, Eli Lilly, 5, kyowa Kirin Pharma, 5; K. Banaszkiewicz: None; B. Butzeck: None; H. Don: None; S. Engelhardt: None; J. Shearman: CSL Behring, 1; D. Mitchell: None; J. Barker: None; V. Brueton: None; P. Coathup: None; J. Dowsett: None; M. Duncan: None; T. Dunleavy: None; I. Fish: None; A. Hoggarth: None; M. McKinnon: None; J. Minter: None; T. Osborne: None; M. Smith: None; C. Wright: None; P. Kiely: Alfasigma, 6, Eli Lilly, 12, Sponsorship to attend educational meetings.

To cite this abstract in AMA style:

Farisogullari B, Machado P, Finzel S, Carroll G, mcCarthy G, Stack J, Parisi S, Porto G, pascal r, Nagy G, Weidl M, Rosenthal A, Guggenbuhl P, Banaszkiewicz K, Butzeck B, Don H, Engelhardt S, Shearman J, Mitchell D, Barker J, Brueton V, Coathup P, Dowsett J, Duncan M, Dunleavy T, Fish I, Hoggarth A, McKinnon M, Minter J, Osborne T, Smith M, Wright C, Kiely P. The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-iron-overload-and-hfe-genetic-mutations-on-joint-disease-in-haemochromatosis-data-from-the-haemochromatosis-arthropathy-inception-cohorts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-iron-overload-and-hfe-genetic-mutations-on-joint-disease-in-haemochromatosis-data-from-the-haemochromatosis-arthropathy-inception-cohorts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology